JV001 / Juvensis Therap - LARVOL DELTA

TELOMERE RECAPPING VIA GENE THERAPY AS A THERAPEUTIC STRATEGY FOR CARDIO-RENAL SYNDROMES TYPE 4 (ISN-WCN 2026) - "This study demonstrates that telomere shortening in cardiomyocytes is characteristic of CRS4.Methods We engineered an adeno-associated virus9 (AAV9) gene therapy overexpressing catalytic inactive and nuclear localized human telomerase reverse transcriptase (modhTERT) under cardiac troponin T (cTnT) promotor (JV001).Download: Download high-res image (152KB)Download: Download full-size imageResults Overexpression of modhTERT recapped myocardial telomeres, reversed cardiac dysfunction, cardiac hypertrophy, cardiac fibrosis and mitochondrial dysfunction in two CRS4 animal models: 5/6 nephrectomy and Angiotensin II-high salt-uninephrectomy murine models...In human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) co-cultured with patients' serum or indoxyl sulfate toxin, hiPSC-CMs exhibited contractile dysfunction. Overexpression of modhTERT also blocked further telomere shortening and reversed contractile dysfunction in hiPSC-CMs.Download: Download..."

Gene therapy • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Fibrosis • Gene Therapies • Heart Failure • Immunology • Metabolic Disorders • Nephrology • Renal Disease • TERT

An Exploratory Clinical Study of JV001 in the Treatment of Patients With Heart Failure Due to Dilated Cardiomyopathy (ChiCTR) - P=N/A | N=12 | Completed | Sponsor: Shanghai East Hospital; Shanghai East Hospital

New trial • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

MERCURY-DCM: Myocardial Telomere Recapping Study for Dilated Cardiomyopathy (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Shanghai East Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Jul 2025

Enrollment closed • Trial completion date • Trial primary completion date • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • CXCL8 • IFNA1 • IFNG • IL10 • IL17A • IL1B • IL2 • IL4 • IL5 • IL6 • ST2 • TNFA

Design of a Pan Heart Failure Gene Therapy by Targeting Telomere-p53 Axis (AHA 2023) - P1 | "These preclinical studies demonstrate considerable potential for the first pan-HF single-dose gene therapy that can reverse cardiac function and prevent myocardial remodeling which would be invaluable clinically and an Investigator Initiated Trial (IIT) (NCT05837143) was launched in April 2023."

Gene therapy • Cardiovascular • Congestive Heart Failure • Fibrosis • Gene Therapies • Heart Failure • Immunology • Metabolic Disorders